This week, leaders in the House and Senate joined to introduce legislation to reform the United State patent system. This follows failed efforts at patent reform in the previous two sessions of Congress. The high-technology industry has long pushed for patent reform, but its efforts have been at odds with the biotechnology and pharmaceutical industries, which are concerned that the legislation would weaken patent protections and consequently cripple their ability to raise capital. We spoke to the Biotechnology Industry Organization’s CEO Jim Greenwood about the new legislation, how it differs from previous versions, and the concerns that remain for the biotech companies.